Plain-English translation of NCT06602557 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether nebulized —an antibiotic delivered as a mist you breathe in—can help treat stubborn bacterial lung infections in patients who are on extracorporeal membrane oxygenation (ECMO), a machine that temporarily does the work of the heart and lungs. The researchers believe that because this machine reduces blood flow to the lungs, regular antibiotics may not reach the infection well enough, so delivering the medication directly into the lungs through inhalation might work better.
Patients on heart-lung support machines get lung infections about 40% of the time, and these infections often don't respond well to standard antibiotics—even when doctors use the right medication. The research team thinks this happens because the support machine changes how much blood reaches the lungs, which may prevent antibiotics from getting where they need to go.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would receive the nebulized medication—which you breathe in like a mist—in addition to your regular intravenous antibiotics and standard care. The research team will monitor your lung function, take samples to check how well the infection is improving, and track your recovery while you are in the intensive care unit on the ECMO machine and breathing tube. The trial involves 26 patients total, and your participation would continue until you improve or until the doctors determine the treatment isn't working.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
France